• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淬冷和研磨的无定形熊去氧胆酸之间结晶行为的差异。

Differences in crystallization behavior between quenched and ground amorphous ursodeoxycholic acid.

作者信息

Yonemochi E, Inoue Y, Buckton G, Moffat A, Oguchi T, Yamamoto K

机构信息

Centre for Materials Science, School of Pharmacy, University of London, UK.

出版信息

Pharm Res. 1999 Jun;16(6):835-40. doi: 10.1023/a:1018817801444.

DOI:10.1023/a:1018817801444
PMID:10397602
Abstract

PURPOSE

To study the crystallization of ground and quenched ursodeoxycholic acid (UDCA) and to characterize their amorphous states.

METHODS

Amorphous UDCA was prepared by grinding and also by rapid cooling of the melt. These samples were characterized by powder X-ray diffraction (XRD), near IR spectra and dynamic water sorption. The heat associated with crystallization was measured in an isothermal microcalorimeter at 25 degrees C at various relative humidities (RH) (50%-100%) and, in the presence of the vapour from a mixed solvent of ethanol and water (ethanol conc. 10%-100%). The specific surface area was calculated from krypton adsorption. Contact angles were measured by using a Wilhelmy plate to calculate the surface energy of the samples.

RESULTS

Ground and quenched samples yielded amorphous XRD patterns. Differential scanning calorimetry thermographs of the milled sample revealed that crystallization occurred at around 80 degrees C, whereas the quenched sample did not crystallize. Exposure to humid air did not result in crystallization of either amorphous sample during the microcalorimetric experiments. In the presence of ethanol vapour, the ground sample did, but the quenched sample did not, crystallize. The amount of water sorption into the quenched sample was larger than that of the ground sample at low RH. The surface energy of the quenched material was different to that of the ground. Peak shifts were observed in the NIR spectra at around 1450, 2100 nm, allowing differentiation between the ground and quenched samples.

CONCLUSIONS

It can be concluded that different molecular states of amorphous UDCA were obtained depending on the preparation method. The crystallisation of amorphous UDCA was related to the molecular state of disorder.

摘要

目的

研究研磨和骤冷熊去氧胆酸(UDCA)的结晶情况,并对其非晶态进行表征。

方法

通过研磨以及熔体快速冷却制备非晶态UDCA。这些样品通过粉末X射线衍射(XRD)、近红外光谱和动态水吸附进行表征。在25℃下,于不同相对湿度(RH)(50%-100%)以及存在乙醇和水的混合溶剂(乙醇浓度10%-100%)的蒸汽条件下,使用等温微量热计测量与结晶相关的热量。通过氪吸附计算比表面积。使用Wilhelmy板测量接触角以计算样品的表面能。

结果

研磨和骤冷样品呈现非晶态XRD图谱。研磨样品的差示扫描量热法热谱图显示结晶在约80℃发生,而骤冷样品未结晶。在微量热实验期间,暴露于潮湿空气中未导致任何一种非晶态样品结晶。在存在乙醇蒸汽的情况下,研磨样品结晶了,但骤冷样品未结晶。在低RH下,骤冷样品的吸水量大于研磨样品。骤冷材料的表面能与研磨材料不同。在近红外光谱中,在约1450、2100nm处观察到峰位移,可区分研磨和骤冷样品。

结论

可以得出结论,根据制备方法可获得非晶态UDCA的不同分子状态。非晶态UDCA的结晶与无序分子状态有关。

相似文献

1
Differences in crystallization behavior between quenched and ground amorphous ursodeoxycholic acid.淬冷和研磨的无定形熊去氧胆酸之间结晶行为的差异。
Pharm Res. 1999 Jun;16(6):835-40. doi: 10.1023/a:1018817801444.
2
Evaluation of amorphous ursodeoxycholic acid by thermal methods.采用热分析法评估无定形熊去氧胆酸。
Pharm Res. 1997 Jun;14(6):798-803. doi: 10.1023/a:1012114825513.
3
Characterization of amorphous ursodeoxycholic acid prepared by spray-drying.喷雾干燥法制备的无定形熊去氧胆酸的表征
J Pharm Pharmacol. 1998 Nov;50(11):1213-9. doi: 10.1111/j.2042-7158.1998.tb03336.x.
4
Factors affecting the apparent solubility of ursodeoxycholic acid in the grinding process.研磨过程中影响熊去氧胆酸表观溶解度的因素。
Int J Pharm. 2003 Apr 14;255(1-2):49-56. doi: 10.1016/s0378-5173(03)00083-8.
5
A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy.一项利用水蒸气吸附和近红外光谱法对无定形硫酸沙丁胺醇结晶过程的研究。
Int J Pharm. 2002 Apr 26;237(1-2):171-8. doi: 10.1016/s0378-5173(02)00038-8.
6
Characterization of melt-quenched and milled amorphous solids of gatifloxacin.加替沙星熔融淬火和研磨非晶态固体的表征
Drug Dev Ind Pharm. 2016 Nov;42(11):1851-6. doi: 10.1080/03639045.2016.1179752. Epub 2016 May 22.
7
Preparation of Amorphous Composite Particles of Drugs with Ursodeoxycholic Acid as Preclinical Formulations.以熊去氧胆酸为临床前制剂的药物无定形复合颗粒的制备。
Chem Pharm Bull (Tokyo). 2019;67(9):921-928. doi: 10.1248/cpb.c18-00644.
8
Differentiated thermal crystallization from amorphous chenodeoxycholic acid between the ground specimens derived from the polymorphs.多晶型物衍生的研磨试样中无定形鹅去氧胆酸的微分热结晶。
Int J Pharm. 2003 Mar 6;253(1-2):81-8. doi: 10.1016/s0378-5173(02)00675-0.
9
Effect of preparation method on physical properties of amorphous trehalose.制备方法对非晶态海藻糖物理性质的影响。
Pharm Res. 2004 Jul;21(7):1167-76. doi: 10.1023/b:pham.0000033003.17251.c3.
10
Studies of the crystallization of amorphous trehalose using simultaneous gravimetric vapor sorption/near IR (GVS/NIR) and "modulated" GVS/NIR.使用同步重量法蒸汽吸附/近红外光谱(GVS/NIR)和“调制”GVS/NIR对无定形海藻糖结晶的研究。
AAPS PharmSciTech. 2009;10(1):297-302. doi: 10.1208/s12249-009-9195-4. Epub 2009 Mar 19.

引用本文的文献

1
Innovations in Thermal Processing: Hot-Melt Extrusion and KinetiSol® Dispersing.热加工创新:热熔挤出和 KinetiSol® 分散技术。
AAPS PharmSciTech. 2020 Nov 8;21(8):312. doi: 10.1208/s12249-020-01854-2.
2
Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds.机械致药物非晶化:冷冻研磨化合物热行为研究。
AAPS PharmSciTech. 2012 Sep;13(3):772-84. doi: 10.1208/s12249-012-9801-8. Epub 2012 May 15.
3
Near-infrared analysis of hydrogen-bonding in glass- and rubber-state amorphous saccharide solids.

本文引用的文献

1
Characteristics and significance of the amorphous state in pharmaceutical systems.药物体系中非晶态的特征与意义。
J Pharm Sci. 1997 Jan;86(1):1-12. doi: 10.1021/js9601896.
玻璃态和橡胶态无定形糖类固体中氢键的近红外分析
AAPS PharmSciTech. 2009;10(2):524-9. doi: 10.1208/s12249-009-9243-0. Epub 2009 May 7.
4
Effect of preparation method on physical properties of amorphous trehalose.制备方法对非晶态海藻糖物理性质的影响。
Pharm Res. 2004 Jul;21(7):1167-76. doi: 10.1023/b:pham.0000033003.17251.c3.